JP2023129495A5 - - Google Patents

Download PDF

Info

Publication number
JP2023129495A5
JP2023129495A5 JP2023116253A JP2023116253A JP2023129495A5 JP 2023129495 A5 JP2023129495 A5 JP 2023129495A5 JP 2023116253 A JP2023116253 A JP 2023116253A JP 2023116253 A JP2023116253 A JP 2023116253A JP 2023129495 A5 JP2023129495 A5 JP 2023129495A5
Authority
JP
Japan
Prior art keywords
alkyl
alkylene
unsubstituted
substituted
absent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023116253A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023129495A (ja
Filing date
Publication date
Priority claimed from JP2020543847A external-priority patent/JP2021513990A/ja
Application filed filed Critical
Publication of JP2023129495A publication Critical patent/JP2023129495A/ja
Publication of JP2023129495A5 publication Critical patent/JP2023129495A5/ja
Pending legal-status Critical Current

Links

JP2023116253A 2018-02-20 2023-07-14 疎水性アウリスタチンf化合物およびそのコンジュゲート Pending JP2023129495A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862633059P 2018-02-20 2018-02-20
US62/633,059 2018-02-20
JP2020543847A JP2021513990A (ja) 2018-02-20 2019-02-20 疎水性アウリスタチンf化合物およびそのコンジュゲート
PCT/US2019/018825 WO2019164987A1 (en) 2018-02-20 2019-02-20 Hydrophobic auristatin f compounds and conjugates thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020543847A Division JP2021513990A (ja) 2018-02-20 2019-02-20 疎水性アウリスタチンf化合物およびそのコンジュゲート

Publications (2)

Publication Number Publication Date
JP2023129495A JP2023129495A (ja) 2023-09-14
JP2023129495A5 true JP2023129495A5 (cg-RX-API-DMAC7.html) 2024-01-31

Family

ID=65904522

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020543847A Pending JP2021513990A (ja) 2018-02-20 2019-02-20 疎水性アウリスタチンf化合物およびそのコンジュゲート
JP2023116253A Pending JP2023129495A (ja) 2018-02-20 2023-07-14 疎水性アウリスタチンf化合物およびそのコンジュゲート

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020543847A Pending JP2021513990A (ja) 2018-02-20 2019-02-20 疎水性アウリスタチンf化合物およびそのコンジュゲート

Country Status (12)

Country Link
US (2) US11857565B2 (cg-RX-API-DMAC7.html)
EP (1) EP3755707A1 (cg-RX-API-DMAC7.html)
JP (2) JP2021513990A (cg-RX-API-DMAC7.html)
KR (1) KR20200122351A (cg-RX-API-DMAC7.html)
CN (1) CN111989339A (cg-RX-API-DMAC7.html)
AU (1) AU2019225845B2 (cg-RX-API-DMAC7.html)
CA (1) CA3090805A1 (cg-RX-API-DMAC7.html)
IL (1) IL276546B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020008267A (cg-RX-API-DMAC7.html)
SG (1) SG11202007540SA (cg-RX-API-DMAC7.html)
TW (1) TWI838358B (cg-RX-API-DMAC7.html)
WO (1) WO2019164987A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024510435A (ja) 2021-03-18 2024-03-07 シージェン インコーポレイテッド 生体活性化合物の内部移行複合体からの選択的薬物放出
WO2022217022A1 (en) 2021-04-10 2022-10-13 Profoundbio Us Co. Folr1 binding agents, conjugates thereof and methods of using the same
CA3216459A1 (en) 2021-04-23 2022-10-27 Profoundbio Us Co. Anti-cd70 antibodies, conjugates thereof and methods of using the same
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
CA3230737A1 (en) 2021-09-03 2023-03-09 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
AR133955A1 (es) 2023-09-26 2025-11-19 Profoundbio Us Co Agentes de unión a ptk7, conjugados de éstos y métodos de uso de los mismos
TW202547866A (zh) 2024-01-10 2025-12-16 丹麥商珍美寶股份有限公司 Slitrk6結合劑、其共軛物及使用彼之方法
WO2025181219A1 (en) 2024-02-29 2025-09-04 Genmab A/S Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2036891B (en) 1978-12-05 1983-05-05 Windsor Smith C Change speed gear
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
EP0941120A4 (en) 1996-11-05 2004-08-18 Bristol Myers Squibb Co BRANCHED PEPTIDLINKERS
ES2369542T3 (es) 2002-07-31 2011-12-01 Seattle Genetics, Inc. Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
ES2708763T3 (es) 2005-07-07 2019-04-11 Seattle Genetics Inc Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C
WO2007086083A1 (en) 2006-01-24 2007-08-02 Tecnoimage Srl Supporting frame for covering elements
WO2008025020A2 (en) 2006-08-25 2008-02-28 Seattle Genetics, Inc. Cd30 binding agents and uses thereof
JP2010519310A (ja) 2007-02-21 2010-06-03 メダレックス インコーポレイテッド 単一のアミノ酸を有する化学リンカーおよびその複合体
WO2009117531A1 (en) 2008-03-18 2009-09-24 Seattle Genetics, Inc. Auristatin drug linker conjugates
PT3156420T (pt) 2010-12-06 2019-05-27 Seattle Genetics Inc Anticorpos humanizados a liv-1 e seu uso para tratar o cancro
CN105017420B (zh) 2012-02-17 2019-05-28 西雅图基因公司 针对整联蛋白αvβ6的抗体和使用该抗体治疗癌症
US9751942B2 (en) 2012-03-29 2017-09-05 Chugai Seiyaku Kabushiki Kaisha Anti-LAMP5 antibody and utilization thereof
CN104640572B (zh) * 2012-05-15 2018-04-27 索伦托医疗有限公司 药物偶联物,偶联方法,及其用途
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
EP3107557B1 (en) 2014-02-17 2021-06-09 Seagen Inc. Hydrophilic antibody-drug conjugates

Similar Documents

Publication Publication Date Title
JP2021513990A5 (cg-RX-API-DMAC7.html)
JP2023082171A5 (cg-RX-API-DMAC7.html)
JP2022105640A5 (cg-RX-API-DMAC7.html)
JP2023534437A5 (cg-RX-API-DMAC7.html)
JP2023524271A5 (cg-RX-API-DMAC7.html)
JP2019524759A5 (cg-RX-API-DMAC7.html)
RU2388765C2 (ru) Натрийуретические соединения, конъюгаты и их применение
RU2018102153A (ru) Конъюгаты антитела и лекарственного средства (adc) и конъюгаты антитела и пролекарства (apdc), содержащие ферментативно расщепляемые группы
RU2015119557A (ru) Конъюгаты лекарственное вещество-белок
US9289510B2 (en) Polymeric drug delivery conjugates and methods of making and using thereof
JP2024513391A5 (cg-RX-API-DMAC7.html)
JP2021138761A5 (cg-RX-API-DMAC7.html)
JP2023542295A5 (cg-RX-API-DMAC7.html)
US20020110535A1 (en) Multivalent platform molecules comprising high molecular weight polyethylene oxide
RU2015119561A (ru) Новые конъюгаты лекарственное вещество-белок
BR112020020466A2 (pt) Conjugados de peptídeo de camptotecina
JP2021521111A5 (cg-RX-API-DMAC7.html)
RU2019105549A (ru) Гидрофильные саморазрушающиеся линкеры и их конъюгаты
RU2010149608A (ru) Антиангиогенные соединения
RU2018102358A (ru) Нацеленные конъюгаты ksp ингибиторов
CA2448319A1 (en) Cytotoxins, prodrugs, linkers and stabilizers useful therefor
JP2019043957A5 (cg-RX-API-DMAC7.html)
ES2792598T3 (es) Métodos para preparar conjugados a partir de proteínas que contienen disulfuro
CN107406496A (zh) 可通过转谷氨酰胺酶缀合的抗体和由其制备的缀合物
JP2024513392A5 (cg-RX-API-DMAC7.html)